N-formylmethionylphenylalanine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-formylmethionylphenylalanine
• 英文别名: 2-[(2-formamido-4-methylsulfanylbutanoyl)amino]-3-phenylpropanoic acid
• 化学式: C₁₅H₂₀N₂O₄S
• 分子量: 324.4
• InChiKey: VZQJQFGSAAGNSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
  申请人：Yoo, Seo Hong

  公开号：EP2255812A1

  公开（公告）日：2010-12-01

  A composition comprising a clear aqueous solution comprising: (a) a first material selected from soluble ursodeoxycholic acid or a sodium salt oftauroursodeoxycholic acid (TUDCA); (b) a carbohydrate selected from the group consisting of an aqueous soluble starch conversion product or an aqueous soluble non-starch polysaccharide; (c) water, wherein the first material and the carbohydrate both remain in solution for any subset of the range of pH values obtainable in an aqueous system sufficient for a pharmaceutical formulation to remain in solution from preparation, to administration, to absorption in the body; for use in the treatment of at least one symptom of a neurodegenerative disease or at least one symptom of a motor neuron disease in a subject.

  一种由透明水溶液组成的组合物，其中包括 (a) 第一种材料，选自可溶性熊去氧胆酸或熊去氧胆酸钠盐 (TUDCA)； (b) 选自水溶性淀粉转化产物或水溶性非淀粉多糖的碳水化合物； (c) 水，其中第一种材料和碳水化合物在水体系中可获得的 pH 值范围的任何子集中均 保持溶液状态，足以使药物制剂从制备、给药到在体内吸收均保持溶液状态； 用于治疗受试者神经退行性疾病的至少一种症状或运动神经元疾病的至少一种症状。
• Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs53 upregulation
  申请人：Martinez-Alonzo Carlos

  公开号：US20050221287A1

  公开（公告）日：2005-10-06

  A method is provided of identifying compounds for use in a pharmaceutical composition having an anti-viral effect against CXCR4-dependent HIV activity comprising: providing a first aliquot of CXCR-4-expressing GH-Tg cells; contacting said first aliquot with HIV particles; providing a second aliquot of CXCR4-expressing GH-Tg cells; contacting said second aliquot with a test ligand; contacting said second aliquot with HIV particles; and isolating virus from said first and said second aliquot of cells, wherein a decrease in the ability to isolate virus from said second aliquot cells indicates said test ligand possess anti-viral activity against HIV. Also provided is a method of identifying compounds for use in a pharmaceutical composition having a therapeutic effect against a disease involving CXCR4-dependent chemotaxis comprising providing a first aliquot CXCR4-expressing GH-Tg cells; contacting said first aliquot with CXCL12; measuring a first migration indes; providing a second aliquot of CXCR4-expressing GH-Tg cells; contacting said second aliquot with CXCL12; contacting said second aliquot with a test ligand; measuring a second migration index; and determing a therapeutic potential. In addition, compounds for us in a pharmaceutical composition having a therapeutic effect against a SOCS3 inhibitable disease are identified by a method comprising: providing a first cell having at least one chemokine receptor expressed thereon, said first cell having been transfected with at least one SOCS construct; contacting said first cell with at least one chemokine, measuring a first migration index; providing a second cell having at least one chemokine receptor expressed thereon, said second cell having been transfected with at least one SOCS construct; contacting said second cell with at least one chemokine; measuring a second migration index; and determining a therapeutic potential subjects having a disease associated with CXCR4-dependent HIV are treated by administering to said subject a therapeutically anti-viral effective amount of a compound that induces the expression of SOCS3 and a pharmaceutically acceptable carrier.

  本发明提供了一种鉴定化合物的方法，该化合物可用于具有抗病毒作用的药物组合物中，该药物组合物具有抗CXCR4依赖性HIV活性，该方法包括提供表达CXCR-4的GH-Tg细胞的第一等分试样；将所述第一等分试样与HIV颗粒接触；提供表达CXCR4的GH-Tg细胞的第二等分试样；将所述第二等分试样与测试配体接触；将所述第二等分试样与HIV颗粒接触；以及从所述第一和所述第二等分试样细胞中分离病毒，其中从所述第二等分试样细胞中分离病毒的能力下降表明所述测试配体具有抗HIV的抗病毒活性。本发明还提供了一种用于鉴定对涉及 CXCR4 依赖性趋化的疾病具有治疗作用的药物组合物中的化合物的方法，该方法包括提供第一等分的表达 CXCR4 的 GH-Tg 细胞；使所述第一等分细胞与 CXCL12 接触；测量第一迁移指数；提供第二等分的表达 CXCR4 的 GH-Tg 细胞；使所述第二等分细胞与 CXCL12 接触；使所述第二等分细胞与测试配体接触；测量第二迁移指数；以及确定治疗潜力。此外，还通过以下方法鉴定了药物组合物中对 SOCS3 可抑制疾病具有治疗效果的化合物：提供具有至少一种趋化因子受体的第一细胞，所述第一细胞已转染至少一种 SOCS 构建物；使所述第一细胞与至少一种趋化因子接触，测量第一迁移指数；提供具有至少一种趋化因子受体的第二细胞，所述第二细胞已转染至少一种 SOCS 构建物；将所述第二细胞与至少一种趋化因子接触；测量第二迁移指数；以及确定治疗潜力 通过向所述受试者施用治疗抗病毒有效量的诱导 SOCS3 表达的化合物和药学上可接受的载体，治疗患有与 CXCR4 依赖性 HIV 相关疾病的受试者。
• METHOD OF DETECTING ADHERENT CELLS
  申请人：MINNESOTA MINING AND MANUFACTURING COMPANY

  公开号：EP0026214A1

  公开（公告）日：1981-04-08
• EP0026214A4
  申请人：——

  公开号：EP0026214A4

  公开（公告）日：1981-08-31
• A DIRECT METHOD FOR DETERMINING ADHERENT CELLS USING A PIEZOELECTRIC OSCILLATOR
  申请人：MINNESOTA MINING AND MANUFACTURING COMPANY

  公开号：EP0026214B1

  公开（公告）日：1983-10-05